A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States
- 4 October 1999
- journal article
- Published by Elsevier BV in Drug and Alcohol Dependence
- Vol. 57 (1), 7-22
- https://doi.org/10.1016/s0376-8716(99)00041-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Postmarketing Surveillance and Adverse Drug ReactionsPublished by American Medical Association (AMA) ,1999
- Craving cocaine cues: cognitive neuroscience meets drug addiction researchTrends in Cognitive Sciences, 1997
- Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cellsEuropean Journal of Pharmacology, 1996
- The undertreatment of pain in ambulatory AIDS patientsPain, 1996
- Neuroleptic Withdrawal in Schizophrenic PatientsArchives of General Psychiatry, 1995
- Pain and Its Treatment in Outpatients with Metastatic CancerNew England Journal of Medicine, 1994
- Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problemsPublished by American Medical Association (AMA) ,1993
- Cellular and Molecular Mechanisms of Drug DependenceScience, 1988
- Adverse-Drug-Reaction MonitoringNew England Journal of Medicine, 1986
- The Treatment of Cancer PainNew England Journal of Medicine, 1985